The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Sterling eases off recent highs as vaccine optimism fades

Thu, 28th Jan 2021 12:23

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv
(Updates prices, adds commentary and detail)

By Elizabeth Howcroft

LONDON, Jan 28 (Reuters) - The British pound retreated on
Thursday from the previous session's multi-month highs, as
investors tempered some of their optimism about the UK vaccine
rollout, with the lockdown in England set to last until at least
March.

Sterling surged to its highest since May 2018 against the
dollar in early London trading on Wednesday and later reached an
eight-month high against the euro - a move analysts attributed
to the UK rolling out vaccines faster than continental Europe.

But concern about vaccine rollouts globally, and the impact
of mutations of the virus, created a cautious tone in markets,
and a stronger dollar, which meant that the British currency
eased off these highs on Thursday.

"In this environment, everything is pointing towards refuge
in the dollar, even if the moves are marginal in today's trading
session," said Simon Harvey, an FX strategist at Monex Europe.

"The pound is not sheltered from this strong USD
environment, despite the UK's aggressive rate of vaccine
distribution, although it remains relatively robust against
other G10 peers," he said.

Britain said on Thursday it must get all the COVID-19
vaccines it had ordered and paid for, after some European Union
politicians asked drugmaker AstraZeneca to divert doses from the
UK to make up for a shortfall in supplies.

At 1156 GMT, the pound was down 0.2% against a stronger
dollar, at $1.3661, compared with its Wednesday high of $1.3759
. Versus the euro, it was down around 0.2% at 88.59
pence per euro, after peaking at 88.135 in the previous session
.

"We consider sterling optimism to be excessive and we see
the risk of disappointed expectations. We therefore urge caution
about betting on further sterling gains," wrote Commerzbank FX
strategist You-Na Park-Heger in a note to clients.

"The markets are clearly ignoring that the current infection
situation in the UK is still very tense," she said. "There is a
high degree of uncertainty as it is difficult to say how the
pandemic is going to develop short-term and when and how quickly
the restrictions can be eased."

Britain has the world's fifth highest death toll from
COVID-19, and Prime Minister Boris Johnson has indicated that
the strict COVID-19 lockdown in England will last until March 8.

British households have cut debit and credit card spending
sharply and the proportion of workers on furlough has risen to
its highest since July after new coronavirus lockdown
restrictions came into force earlier this month.
(Reporting by Elizabeth Howcroft; editing by William Maclean,
Larry King)

More News
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.